The Health Care Cost Institute (HCCI) conducted an analysis on estimated acquisition costs and ESI reimbursement costs among 340B-participating hospitals in 2022. This issue brief analyzes the estimated ESI and Medicare fee-for-service price mark-up, relative to estimated acquisition costs, among 340B hospitals. Among the three physician-administered drugs of interests: daratumumab, pegfilgrastim, and infliximab, we found that 340B hospitals received a markup range between 3.9 and 10.6 times the estimated acquisition costs among ESI payers and markup range between 1.6 and 2.9 times the estimated acquisition cost among Medicare fee-for-service.
